The blood loss data and transfusion requirements including blood bank, salvaged washed red cells, fresh frozen plasma and cryoprecipitate were analysed for the first 75 cases of liver transplantation performed at the Austin Hospital between June 1988 and October 1992.
general information and
A liver transplant operation involves three stages. Stage I is pre-anhepatic and involves dissection and mobilization of the diseased liver. Stage Il is the anhepatic period when there is no liver circulation. Veno-venous (femoro-portal to axilla) bypass may be used at this stage to lessen the haemodynamic effect of inferior vena cava cross-clamping. Venous bypass was used in 30 cases initially in this series. Subsequently a modification of surgical technique involving only partial caval clamping was developed and venous bypass was not used in the latter 45 cases. This stage requires removal of the diseased liver and placement of the donor liver orthotopically. Stage III is reperfusion and begins with re-establishment of portal and caval blood flow. After hepatic arterial anastomosis, biliary reconstruction is performed using either a choledocho-choledochostomy or a choledochojejunostomy via a roux loop.
At times I + 60 (min), I + 120, II + 30, III -5, III + 5, III + 30, III + 60, and III + 120 blood samples were taken for measurement of haemoglobin concentration, platelet count, coagulation profile and thrombelastography (TEG). Transfusion therapy was given to a target haemoglobin of 10 g/dl, clinically acceptable haemodynamics and satisfactory urine output. Blood loss was estimated by assessment of replacement requirements including autologous transfusion. Component therapy (fresh frozen plasma, platelets and cryoprecipitate) was given according to combined assessment of laboratory coagulation profile, thrombelastographic pattern and clinical bleeding tendency. Figure 1 shows the haemoglobin concentration throughout the operation and reflects the attempt to maintain a level of 10 g/dl. Table 3 contains the data for blood loss and blood product use for the whole series of 75 consecutive liver transplant operations. The mean blood loss was 8.8 litres with a median value of 4 litres. Blood bank component use was not universal with 870/0, 75%, 43%, and 15070 respectively requmng packed cells, FFP, platelets, and cryoprecipitate. Autologous transfusion was used in 61 out of the 75 cases with a mean of 3.9 units of washed cells per patient. Figure 2 demonstrates that in 42 out of 75 cases (56070) blood loss was less than 5 litres and in 60 out of 75 cases (80070) it was less than 10 litres. This graphically shows that estimated blood loss is more appropriately represented by the median value rather than the mean. There were seven patients whose blood loss exceeded 15 litres and in three of these it was greater than 50 litres. Most of the cases with massive bleeding occurred early in the transplant program. In the first 25 cases 16 (64070) had less than 10 litres blood loss compared with 21 out of 25 (84070) and 23 out of 25 (92070) in the second and third groups. There was a significant difference (P<O.OI) between the mean and median blood loss in the first 25 cases (16.3 and 8 respectively) when compared with the second (6.0 and 4) and third (4.0 and 3) groups (Table 4 ). The progressive reduction in blood loss and blood product use is shown in Figure 3 which compares the first 25, second 25, and third 25 sequential transplants. Significantly, fewer units of bank RBCs, FFP, platelets and cryoprecipitate were used in the latter two groups when compared to the first (P<O.01 and/or P<O.05).
RESULTS
FIGURE 3: Comparison of blood loss and blood product use between first, second and third 25 liver transplants. Table 5 shows the blood loss data in the various aetiologies of liver disease. Patients with alcoholic cirrhosis lost the most blood and those with cholestatic or metabolic disease had modest blood loss. 
DISCUSSION
Liver transplantation carries a risk of excessive bleeding due to the combination of specific surgical factors and multifactorial abnormalities of coagulation, both pre-existing as well as those which occur during surgery itself . Surgical risk factors for excessive bleeding intraoperatively include portal hypertension with the presence of an extensive collateral circulation. Surgical access may also be restricted by scarring and adhesions either from inflammatory disease or previous hepatobiliary surgery?
In the decade since 1983 liver transplant centres world-wide have reported progressively less perioperative bleeding over time. This has been attributed to improvements in both surgical technique and anaesthesia managements. In our series the progressive reduction in blood loss and transfusion requirement is demonstrated by the comparison between the first, second and third groups of 25 cases. This is attributed mainly to increasing surgical experience. In addition, in the early stages of this program most of the cases were extremely high-risk patients who were likely to suffer a higher rate of complications including bleeding. Of the four cases with blood loss in excess of 20 litres (Case 1, 60 litres; Case 11, 20 litres; Case 12, 65 litres; and Case 17, 90 litres) all of them had severe portal hypertension and two had previously undergone hepatobiliary surgery. As a liver transplant unit gains experience, surgery is increasingly offered as well to patients at lower risk. This broad mix of risk categories also partly accounts for the reduction in numbers of cases with excessive bleeding over time.
The role of veno-venous bypass in reducing bleeding has been debated 9 ,1O. Portal vein cross-clamping without decompression via bypass will increase venous pressure and may contribute to surgical bleeding during the an hepatic stage. In this series venous bypass was used in only 30 cases. Subsequently a modification of surgical technique involving only partial inferior vena caval clamping has been used 11. With this latter approach, haemodynamic stability is maintained without the need for bypass although there is no portal decompression. There was certainly no indication in our experience that the change to no bypass made surgical bleeding more likely. Despite the theoretical advantages of venous bypass in this respect it seems to have an inconsequential role in perioperative blood loss.
Autologous transfusion with intraoperative salvage and washing of red cells was available in all but the first four cases. It was used in 61 patients. Most liver transplant centres use this technique to reduce dependence on bank blood. Although some cast doubt on its cost-effectiveness 12 , its efficacy is most obvious in cases of massive blood loss. One patient in this series had 40 litres of blood salvaged facilitating re-transfusion of the equivalent of 36 This reduction in demand of bank blood resources of 30070 is similar to that reported in other centres which have demonstrated the safety and efficacy of autologous transfusion in liver transplantation 13 -17 • Most patients presenting for liver transplantation have abnormal coagulation function, ranging through factor deficiencies, thrombocytopenia and varying degrees of disseminated intravascular coagulation 4
•
Predicting perioperative blood loss on the basis of preexisting coagulopathy has been attempted by several investigators 2 ,7,'8,'9. One group found a significant correlation between blood product use and preoperative coagulopathyl8, while another failed to show any predictive value of preoperative coagulation screen l9 • The aetiology of the underlying liver disease as a risk factor for bleeding has also been investigated 2 ,3,2o,21. One group reported greater blood product requirement in patients with parenchymal disease such as chronic active hepatitis compared with cholestatic conditions such as sclerosing cholangitis and primary biliary cirrhosis 20 • However, this was not statistically significant. Whether patients with alcoholic cirrhosis are more likely to bleed is also unproven, although the well documented severity of coagulopathy in these patients 22 accompanies a strong clinical impression that they do bleed more. On the other hand, primary biliary cirrhosis patients usually have less bleeding and such cholestatic conditions may in fact be associated with an hypercoagulable tendency23. Our data support these findings in that alcoholic cirrhosis patients bled most and those with either cholestatic or metabolic disease had the lowest blood loss.
In addition to pre-existing coagulation disturbance, liver transplant surgery itself causes specific abnormalities 4 ,5,24. First, fibrinolysis is common, occurring during the dissection and anhepatic stages as well as with reperfusion 5 ,25,26. Second, reperfusion is universally associated with a coagulopathy which has been investigated and probably has several aetiologies 5 ,27. It is at least partly attributed to graft ischaemia and reperfusion. Finally if there has been more than moderate blood loss there may be superimposed clotting defects associated with massive transfusion, including dilution.
Strategies to deal with both pre-existing and intraoperative coagulopathies vary. It has been recommended that FFP, platelets and cryoprecipitate should be administered according to abnormal laboratory and thrombelastographic results 24 • Another approach is to prophylactically administer anti-fibrinolytic therapy. The non-specific serine protease inhibitor aprotinin has been used in this setting with claims of reduced perioperative blood loss and blood product require-ment2 8 ,29. Epsilon-aminocaproic acid (t-ACA) has also been used to treat demonstrable fibrinolysisJO, but is not thought to be useful prophylacticallyJ I.
Preservative-free aprotinin is expensive and not easily available in Australia, and no patient in our series was given prophylactic anti-fibrinolytics. Several patients were given bolus doses of E-ACA when bleeding was excessive and fibrinolysis was detected on the TEG. Given the relatively modest transfusion requirements for the majority of patients in our series, there is a concern that prophylactic administration of antifibrinolytics is unnecessary and potentially harmful. There are reports that the postoperative period is associated with a tendency for hypercoagulability and hence aggressive intraoperative therapy may increase the risk of thrombotic events, especially hepatic artery thrombosisJ 2 -J 4 • The same logic applies to blood component administration. It is unnecessary, wasteful and potentially harmful to give FFP, platelets or cryoprecipitate unless specific indications exist. Such therapy should be reserved for situations when there is a clinically obvious bleeding tendency such as excessive blood in the operative field, wound ooze and/or bleeding from intravascular insertion sites. When these are present, specific therapy is guided by changes in the thrombelastogram backed up by laboratory coagulation profile and platelet count. Given the predictable pattern of coagulopathy during liver transplantation, empirical administration is unjustified.
In conclusion, the results for operative blood loss and blood product use in this series of the first 75 cases of liver transplantation performed at the Austin Hospital show that this surgery can be performed without a devastating effect on blood bank reserves. At the commencement of the program the blood bank made available at the start of each case 40 units of blood, 30 units of fresh frozen plasma and platelets and 16 units of cryoprecipitate. As a result of this analysis we now commence a transplant with 16 units each of red cells and FFP, 12 units of platelets and 6 units of cryoprecipitate. Back-up is readily provided in the occasional circumstance when excessive bleeding occurs.
